Literature DB >> 3479839

Indexes of severity for osteoarthritis of the hip and knee. Validation--value in comparison with other assessment tests.

M G Lequesne1, C Mery, M Samson, P Gerard.   

Abstract

The index for hip disease (ISH) was established, validated and appraised as a new assessment test for the trial of new drugs as well as for long-term follow-up of patients, and to help with future indications for surgery. The ISH deals with pain, maximum walking distance, and some activities of daily living. Inter-observer reproducibility is good (mean deviation 0.55 points; p less than 0.05). In a short-term, double-blind crossover trial, the ISH, judged according to its power to distinguish between the active drug period and the placebo period, appears as one of the best assessment tests. In the long term, total hip prosthesis is most often justified when the ISH score reaches 10-12 points. The index of severity for knee disease (ISK) was validated and appraised by the same statistical methods. Its value in non-steroidal anti-inflammatory drug (NSAID) or analgesic trials is lower than the value of the ISH. However, its use is still justified for that purpose, and for long-term follow-up of osteoarthritis of the knee.

Entities:  

Mesh:

Year:  1987        PMID: 3479839     DOI: 10.3109/03009748709102182

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  181 in total

1.  Body composition and muscle strength in women scheduled for a knee or hip replacement. A comparative study of two groups of osteoarthritic women.

Authors:  O R Madsen; C Brot; M M Petersen; O H Sørensen
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

2.  Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee--a double-blind prospective randomized study.

Authors:  Naseer M Akhtar; Rizwan Naseer; Abid Z Farooqi; Wajahat Aziz; Mussadeq Nazir
Journal:  Clin Rheumatol       Date:  2004-07-24       Impact factor: 2.980

3.  Radiological progression of hip osteoarthritis: definition, risk factors and correlations with clinical status.

Authors:  M Dougados; A Gueguen; M Nguyen; L Berdah; M Lequesne; B Mazieres; E Vignon
Journal:  Ann Rheum Dis       Date:  1996-06       Impact factor: 19.103

4.  Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI.

Authors:  J-J Railhac; M Zaim; A-S Saurel; J Vial; B Fournie
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

5.  Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee.

Authors:  Karel Pavelka; Philippe Coste; Pál Géher; Gerhard Krejci
Journal:  Clin Rheumatol       Date:  2010-02-24       Impact factor: 2.980

6.  Validation of a modified Thai version of the Western Ontario and McMaster (WOMAC) osteoarthritis index for knee osteoarthritis.

Authors:  Vilai Kuptniratsaikul; Manee Rattanachaiyanont
Journal:  Clin Rheumatol       Date:  2007-02-20       Impact factor: 2.980

7.  Sex differences in hip osteoarthritis: results of a longitudinal study in 508 patients.

Authors:  J F Maillefert; A Gueguen; M Monreal; M Nguyen; L Berdah; M Lequesne; B Mazieres; E Vignon; M Dougados
Journal:  Ann Rheum Dis       Date:  2003-10       Impact factor: 19.103

Review 8.  Diclofenac/misoprostol. A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis.

Authors:  W W Downie
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  THE CLINICAL, FUNCTIONAL AND BIOMECHANICAL PRESENTATION OF PATIENTS WITH SYMPTOMATIC HIP ABDUCTOR TENDON TEARS.

Authors:  Jay R Ebert; Theertha Retheesh; Rinky Mutreja; Gregory C Janes
Journal:  Int J Sports Phys Ther       Date:  2016-10

10.  [Radiotherapy in painful gonarthrosis. Results of a national patterns-of-care study].

Authors:  Ralph Mücke; M Heinrich Seegenschmiedt; Reinhard Heyd; Ulrich Schäfer; Franz-Josef Prott; Michael Glatzel; Oliver Micke
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.